Noxopharm Ltd.ASX: NOX

Publications Positive Review of Veyonda in Chemotherapy

· Issued by Noxopharm Ltd.

Filed with ASX · · 4 pages · English

® ® • (CEP) Chemo-Enhancing Program isone of the Company’s4-pillars Veyonda clinical programdesigned to establish Veyonda as a blockbuster drug • Aim of CEP is to show that Veyonda boosts the effectiveness of conventional chemotherapy to allow use of lower, safer dosages of chemotherapy • CEP-1 delivers proof-of-concept with Veyonda + low dosages of carboplatin resulting in positive anti-cancer ou

Noxopharm Ltd. on 6ix

Story so far

Earlier from Noxopharm

Later from Noxopharm

All Noxopharm news releases